I’ve served as principal investigator, co-principal investigator, site principal investigator or co-investigator for more than 50 clinical research trials. My latest study focused on strategies to improve outcomes and quality of life for patients who’ve suffered impairments following radical bladder cancer surgery.
At The Ohio State University I’m a tenured professor of urology and serve as chair of the department of urology for Ohio State’s Wexner Medical Center. Additionally, I serve in several national roles: as an oral board examiner of the American Board of Urology, as a member of the Education Council of the American Urological Association (AUA) and as a long-time postgraduate course director for the AUA.
I feel extremely fortunate and proud to be affiliated with the OSUCCC – James. In addition to our research, we’re committed to providing truly individualized care that focuses on total wellness. Our facilities are phenomenal and allow me to provide state-of-the-art care.
- Named to the Castle Connolly list of America’s “Top Doctors” for 2017
Albany Medical College
University of North Carolina Hospitals
7/1/1992 - 6/30/1993
University of Michigan Hospitals
7/1/1993 - 6/30/1997
Specialties and conditions I treat
- Bladder Cancer
- Urethral Cancers
- Urologic Diseases
- Urogenital Cancers
Locations where I practice
Eye and Ear Institute
More about my work
Memorial Sloan-Kettering Cancer Center
7/1/1997 - 6/30/2000
American Board of Urology
News about me
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/17, Dr. Lee has reported no financial relationships with medical device, research and/or drug companies.